COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS

Annually, all over the world there are 300 000 new patients with leukemia (approximately 3% of all oncology diseases), and mortality due to leukemia is 220 000 patients. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of pa...

Full description

Saved in:
Bibliographic Details
Main Authors: R. I. Yagudina (Author), A. Yu. Kulikov (Author), I. A. Komarov (Author)
Format: Book
Published: IRBIS LLC, 2015-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available